Member Info for Newuncle

LOFL

Krull,

Most plcs will not discuss details of anything ongoing as it's "commercially sensitive" and if it's not been RNSd it's not for discussion. I doubt the Webinar will elaborate on that today but be focused on the bits they like which is the science etc.

The real time for challenging the management on funding beyond Q1 2024 will be at the AGM.

Krull,

Just read the last placing notes and they stated very clearly that a CIRT agreement with (I am guessing BUPA?) would not have a material effect in the short term.....hmmmmm

Immediate priorities for CiRT include 1) supporting growth in orders through direct contact with doctors and facilitated peer group events; 2) seeking coverage policies or ensuring the test is added to existing policies with payors; 3) establishing a reimbursement value with the Medicare Administrative Contractors (MAC) and processing claims; and 4) introducing the test to new healthcare systems (for example US integrated delivery networks (IDNs) or UK private medical providers or insurers). The Company is currently in discussions with two UK-based private medical groups for the use of CiRT, including one at an advanced stage of negotiation. It is not expected that the successful conclusion of such discussions would have a material impact on the Company's financial performance in the short term. The Company will announce any agreement in due course.

Krull, discussions on future projects, no timelines yet.

Critical importance now is addressing cashflow from PSE and CIRT via partnerships.

Hence the sell off today. Not too late to avoid a placing but cutting it mighty fine now.

I guess this is the results of scientists/inventors running their own companies, reminds so much of classic Dragon's Den episodes where owners won't accept dilution to achieve the bigger prize of access to markets and think they can do it all by themselves because it's their product/business, if only the good doctors had brought a Peter Jones type character in early here instead of trying to go it alone (lack of Summer sales of CIRT due to unforeseen staff absence) oh come on, really, is this a plc or not?

Management will be fully aware of their cash position/cash burn v income.

They clearly will have to choose how to address that:

1 Another placing

2 Do nothing if revenues grow very fast

3 Bring on board partners to commercialise their products now

I would have hoped they would have addressed the above well ahead of today's RNS but there's nothing in today's RNS I can see about bring on partners specifically for PSE Test which I am at a loss to understand especially when they are talking to potential partners about their other two pipeline projects now. Why have they not adopted such an approach for PSE and CIRT in the USA? Instead they are using limited in house sales people to sell into the markets, do their people even get their calls or emails for a meeting returned I wonder?

Seems so strange that for two pipeline projects they engaging with potential partners right now ahead of launch but not for PSE and CIRT, I think someone dropped the ball on this strategy and now we see the effect that having great products simply ain't enough when you know need cashflow to keep up with costs of close to £1m per month and when you have limited funds in the bank.

Nothing worse than mindless rampers eh....

Posted in: OBD "Of all the stocks I hold this is the one truly I believe could go all the way. It's in a different league from the average aim biotech trading on distant hope. Here we have products ready to go, cash being generated and a ground breaking pipeline."

Tell you what I fekin give up here, can't be bothered with it all.

Bye

I did earlier, word for word from their note

When (not if) OBD deliver just 150 CIRT and 1000 PSE tests a month they would generating income of £1m a month at huge margins, I don't believe we are far away from that at all and in fact 144 PSE tests in first 2 weeks of Jan confirms that. Exponential testing growth = exponential revenues.

From today's RNS...people need to do their fekin research here

Post-year end highlights

§ Unique CPT-PLA code assigned for PSE, available for use from 1 January 2024, enabling accurate reimbursement in the US from Medicare, Medicaid or private payors

USA State efforts to ensure prostate cancer screening coverage

Many states have laws requiring private health insurers to cover tests to detect prostate cancer, including the PSA test and digital rectal exam (DRE). Some states also assure that public employee benefit health plans provide coverage for prostate cancer screening tests.

Most state laws assure annual coverage for men ages 50 and over and for high-risk men, ages 40 and over. “High-risk men” typically refers to African American men and/or men with a family history of prostate cancer. Some states have slightly different coverage requirements.

Laws on coverage vary from state to state, so check with your insurer or with your state insurance commissioner’s office to learn what’s covered.

Medicare coverage

Medicare covers a PSA blood test and a DRE once a year for all men with Medicare age 50 and over.

PSA test: You pay nothing for a yearly PSA blood test. If you get the test from a doctor who doesn’t accept assignment, you may have to pay a fee for the doctor’s services, but not for the test itself.

Digital rectal exam: If your doctor does this test, you pay 20% of the Medicare-approved amount for a yearly DRE and for your doctor’s services related to the exam. The Part B deductible applies. If the DRE is done in a hospital outpatient setting, there is a copayment.

Just confirms my view that at least one major pharma distributor will be brought in very soon.

If I could criticise anything it would the fact they didn't get some bigger players on board sooner re partners to sell through to capture significant volumes but clearly the BoD are aware of that and have said they will execute actions to make that happen sooner rather than later. When those RNSs hit the market that will be a game changer.

I also expect to see larger buyers showing via Shore Cap client base.

Today's sell off is just daft, under researched people panicking because they saw the drop in the SP by traders exiting on mass. Can't change that now. Anyone with a bit of research can see what's coming here and in short order. I expect to see a very much different valuation of the business coming. Commercialisation is just starting here but it seems many wanted instant big numbers, company is in the best place it has ever been now.

That tells me they could not have bought the PSE tests prior to 1 Jan 2024 and that quote below was from today's RNS, just trying to be factual as they say

An application for a unique CPT-PLA? code for PSE was submitted in early July 2023 and the code, 0433U, was assigned in September 2023 and has been available for use by Medicare, Medicaid and private payors from 1 January 2024.

Tikor they sold 144 PSE tests via their reimbursement code since 1 Jan 2024 (according to Shore Cap note)